Loxo Oncology (LOXO) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Loxo Oncology Announces First Quarter 2016 Financial Results
May 4, 2016 6:45 AM EDT
STAMFORD, Conn., May 04, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2016. Loxo Oncology will not be conducting a conference call in conjunction with this earnings release.
"With cash runway well into 2018, we are nicely positioned to bring our programs through new and meaningful milestones, said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. In the first half of 2016, we were able... More
